Novartis Inks $20M Deal To End Texas Medicaid Fraud Suit
Novartis Pharmaceuticals Corp. will shell out nearly $20 million to settle a former employee's whistleblower lawsuit accusing the drugmaker of ripping off Medicaid by promoting off-label uses of eczema treatment Elidel,...To view the full article, register now.
Already a subscriber? Click here to view full article